Correction To: LncRNA MYLK-AS1 Facilitates Tumor Progression and Angiogenesis by Targeting MiR-424-5p/E2F7 Axis and Activating VEGFR-2 Signaling Pathway in Hepatocellular Carcinoma

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2020 Dec 10

PMID 33298087

Citations 5

Authors

Fei Teng

Ju-Xiang Zhang

Qi-Meng Chang

Xu-Bo Wu

Wei-Guo Tang

Jian-Fa Wang

Jin-Feng Feng

Zi-Ping Zhang

Zhi-Qiu Hu

Affiliations

Soon will be listed here.

Citing Articles

LncRNA MSTO2P affects the proliferation, invasion and migration of non-small cell lung cancer by regulating the Wnt/β-catenin pathway.

Chen Y, Shi H, Dong Y, Cui W Discov Oncol. 2025; 16(1):150.

PMID: 39928213 PMC: 11811353. DOI: 10.1007/s12672-025-01920-w.

The role of competing endogenous RNA network in the development of hepatocellular carcinoma: potential therapeutic targets.

Tang Z, Li X, Zheng Y, Liu J, Liu C, Li X Front Cell Dev Biol. 2024; 12:1341999.

PMID: 38357004 PMC: 10864455. DOI: 10.3389/fcell.2024.1341999.

bestDEG: a web-based application automatically combines various tools to precisely predict differentially expressed genes (DEGs) from RNA-Seq data.

Sangket U, Yodsawat P, Nuanpirom J, Sathapondecha P PeerJ. 2022; 10:e14344.

PMID: 36389403 PMC: 9657178. DOI: 10.7717/peerj.14344.

The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer.

Liu J, Zhang Q, Yang D, Xie F, Wang Z Mol Ther Nucleic Acids. 2022; 28:397-407.

PMID: 35505957 PMC: 9038520. DOI: 10.1016/j.omtn.2022.03.012.

Long Non-Coding RNA LINC01572 Promotes Hepatocellular Carcinoma Progression Sponging miR-195-5p to Enhance PFKFB4-Mediated Glycolysis and PI3K/AKT Activation.

Lai S, Quan Z, Hao Y, Liu J, Wang Z, Dai L Front Cell Dev Biol. 2021; 9:783088.

PMID: 34970545 PMC: 8712893. DOI: 10.3389/fcell.2021.783088.

References

Teng F, Zhang J, Chang Q, Wu X, Tang W, Wang J . LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020; 39(1):235. PMC: 7650167. DOI: 10.1186/s13046-020-01739-z. View